Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
- José Galindo1,
- Mauricio Gabrielli1,
- Juan Francisco Guerra1,
- Juan Carlos Cassina1,
- Marcelo Garrido2,
- Nicolás Jarufe1,
- Yerko Borghero2,
- Jorge Madrid2,
- Pablo Zoroquiain3,
- Juan Carlos Roa3 and
- Jorge Martínez1Email author
© Galindo et al.; licensee BioMed Central Ltd. 2013
Received: 5 July 2012
Accepted: 25 January 2013
Published: 5 February 2013
Pancreatic cancer remains as one of the most aggressive human neoplasms, with overall poor survival rates. Radical surgery of the primary lesion is the best option for treatment. Borderline resectable pancreatic tumors (BRPT), defined as partial involvement of peripancreatic vasculature, may benefit from neoadjuvant therapy. We report on the first two BRPT cases treated with neoadjuvant chemoradiation at our institution. Preoperative CT and MRI demonstrated pancreatic tumors encasing the porto-mesenteric confluence suggestive of BRPT. Patients received neoadjuvant chemotherapy (gemcitabine/cisplatin), followed by radiochemotherapy. After treatment, follow-up images demonstrated tumor downsize, allowing for the tumors to be considered then as resectable. They underwent partial pancreatoduodenectomies (Whipple procedure). In case 1, histopathology revealed a complete, margin-free resection, whereas in case 2 there was a complete pathological response, with no evidence of residual tumor. According to the literature, our initial experience using neoadjuvant chemoradiotherapy on BRPT allowed us to downsize the tumor and, subsequently, to perform a curative surgery.
KeywordsBorderline resectable pancreatic cancer Neoadjuvant chemoradiation
Borderline resectable pancreatic tumors
Superior mesenteric artery
Superior mesenteric vein
Pancreatic adenocarcinoma remains as one of the most devastating human cancers, with an overall 5-year survival of <5% . Most patients are diagnosed with advanced disease and only 10 to 20% of patients are resectable at the time of diagnosis . Radical surgery (R0 resection) of the primary tumor and regional lymph node dissection offers the only chance of long-term survival, but unfortunately the majority of those patients treated with curative surgical resection will eventually recur regionally or develop distant metastases [3, 4].
Pancreatic tumors can be classified as resectable (stage I or II), locally advanced (stage III), or metastatic (stage IV). However, with recent advances in pancreatic imaging and surgical techniques, a distinct subset of tumors is emerging that blurs the distinction between resectable and locally advanced disease: tumors of ‘borderline resectability’ . This group includes tumors that exhibit encasement of a short segment of the hepatic artery, without evidence of tumor extension to the celiac axis (CA) and tumor abutment of the superior mesenteric artery (SMA) involving <180° of the circumference of the artery; or short-segment occlusion of the superior mesenteric vein (SMV), portal vein (PV), or their confluence . There is no consensus regarding the management of borderline resectable pancreatic tumors (BRPT). Several studies have suggested that the margin resection status is a very important prognostic factor and that a margin-positive resection strongly predicts early recurrence and short survival [5–8]. Neoadjuvant therapy of BRPT potentially can increase the likelihood of a margin-free resection. Also, it can serve as a biological marker of response to treatment . We report our first two BRPT cases treated initially with neoadjuvant chemoradiation and subsequent radical surgery.
A biliary stent was placed, and relief of jaundice was achieved. He then commenced chemotherapy with gemcitabine (1,000 gm/m2) in combination with cisplatin (50 mg/m2) every two weeks. The patient completed three cycles of chemotherapy. During chemotherapy, cross sectional imaging suggested partial tumor regression, with increased patency of PV (compromise <180°) and less compromise of SMA (<90°), with no evidence of metastatic disease. The patient was referred for consolidation radiotherapy, of which he had a total of 50.4 Gy in 30 fractions and infusional 5-fluorouracil (200 mg/m2). He developed no major adverse effects.
Follow-up CT demonstrated reduction in local disease (Figure 3C,D). Eleven months after the initial diagnosis the patient underwent surgery with curative intent in the form of a Whipple procedure. He had an uneventful recovery period.
Pancreatic cancer is a devastating malignancy with a 5-year overall survival of about 4% . Margin-free resection of the tumor is considered the only chance of cure for these patients, although only 10 to 20% of the tumors are deemed to be resectable at the time of diagnosis. For most patients, curative surgery is not possible because of systemic metastases, advanced nodal disease or a localized tumor that is not amenable of resection due to invasion of adjacent vital structures .
Recently, the designation of borderline resectable tumors has emerged to describe a subpopulation of potentially resectable tumors. For tumors of the head or uncinate process, these criteria include SMV/PV compromise, SMA abutment, encasement of the gastroduodenal artery up to its origin at the hepatic artery, limited inferior vena cava involvement, short-segment SMV occlusion, and colon or mesocolon invasion .
Patients with borderline resectable tumors treated with surgical resection alone can be expected to have a higher rate of local and systemic disease recurrence and worse survival compared with patients who presented with initially resectable disease. This may be related to technical aspects (more difficult surgery), the advanced nature of the tumor, and the high risk for margin-positive resection. Therefore, the goal in the management of the borderline resectable patient is to maximize the chance of a complete resection, which may be accomplished by the use of neoadjuvant therapy .
The role of neoadjuvant therapy in borderline resectable disease is a highly debated topic [8, 9]. This modality of treatment may allow tumor downsizing, reduce the incidence of positive resection margins, delivery of treatment to intact well-vascularized tissues, and higher rates of treatment completion. Also, it facilitates selection for surgery of patients with favorable tumor behavior. Patients who do not develop progressive disease prior to rescue surgery or patients with significant downsize response may have a better prognosis, and moreover, those with poor tumor biology are selected out via disease progression, thereby avoiding the morbidity of futile surgery .
Katz et al. reported on a group of patients with borderline resectable pancreatic adenocarcinoma treated with neoadjuvant chemoradiotherapy; 125 patients received this modality of treatment. Of these, 66 (41%) underwent pancreatectomy. Negative margin was obtained in 94% of the cases. Median survival was 40 months for patients who completed all therapy and 13 months for patients who did not undergo surgery . McClaine et al. reported a 46% rate of surgical resection in a cohort of 26 patients with borderline pancreatic adenocarcinoma who underwent neoadjuvant chemoradiotherapy; 67% of them had a margin free resection. Median survival for resected patients was 23.3 months vs. 15.5 months for non-resected cases . These two studies included a different number of patients; however, the difference was statistically significant in both. In another study, Brown et al. reported a cohort of 13 patients with borderline pancreatic adenocarcinoma who received neoadjuvant therapy. In 11 of 13 patients a margin-negative resection was achieved and nine patients were alive at 20 months follow-up . A systematic review analyzed the role of neoadjuvant chemoradiotherapy for the treatment of both resectable and initially labeled as unresectable pancreatic cancer . This study demonstrated that patients with unresectable pancreatic cancer who underwent neoadjuvant chemoradiotherapy achieved comparable 1-year survival as those with initially resectable disease; 40% of borderline or unresectable cases were ultimately resected. Also, it was not associated with a statistically significant increase in the rate of pancreatic fistula or overall complications in the chemoradiation group.
Our initial experience in these two cases with borderline resectable tumors treated with neoadjuvant chemoradiation is encouraging. We recognize that the decision to offer this modality of treatment not having a biopsy suggestive of pancreatic adenocarcinoma (Case 2) might be debatable, but at the same time we believe that its radiological response made a neoplasm the most likely diagnosis, considering that other etiologies, such as chronic pancreatitis, should not be affected by chemoradiation. In any case, these results are consistent with the published literature, suggesting a clear benefit in terms of curative surgical resection. At this time our center is actively enrolling more patients to be considered for this modality of treatment.
Written informed consents were obtained from the patients for publication of these cases reports and any accompanying images. Copies of the written consents are available for review by the editor-in-chief of this journal.
This research has been performed with the approval of ethics committee of our institution.
- Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ: Cronin KA (eds): SEER Cancer Statistics Review, 1975–2008 . Bethesda, MD: National Cancer Institute; 2011.
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277–300.PubMedView Article
- Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66:56–61.PubMedView Article
- Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567–579.PubMedView Article
- Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13:1035–1046.PubMedView Article
- Khan AZ, Pistinis V, Mudan SS: Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: challenging the boundaries. World J Gastroenterol 2007, 13:6433–6435.PubMedView Article
- Brown KM: Multidisciplinary approach to tumors of the pancreas and biliary tree. Surg Clin North Am 2009, 89:115–131.PubMedView Article
- Tucker ON, Rela M: Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement. HPB Surg 2008, 2008:839503.PubMedView Article
- Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB 3rd: Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients . Expert Rev Anticancer Ther 2011, 11:1555–1565.PubMedView Article
- Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA: The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother 2009, 13:123–143.PubMedView Article
- Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008, 206:833–846. Discussion 846–848PubMedView Article
- McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA: Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2010, 12:73–79.View Article
- Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, Li T, Ciocca V, Cooper H, Hoffman JP: Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008, 195:318–321.PubMedView Article
- Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C: A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011, 15:2059–2069.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.